Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders

Bone Marrow Transplantation

Volumn 34, Issue 8, 2004, Pages 693-702

  Olivieri, A ^a   Scortechini, I ^a   Capelli, D ^a   Montanari, M ^a   Lucesole, M ^a   Gini, G ^a   Troiani, M ^a   Offidani, M ^a   Poloni, A ^a   Masia, M C ^a   Raggetti, G M ^a,b   Leoni, P ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Ospedale Regionale Torrette   (Italy)

Author keywords

Autologous transplantation; Engraftment kinetics; Erythropoietin

Indexed keywords

AMIFOSTINE; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARMUSTINE; CHLORHEXIDINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; MELPHALAN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG COST; FEBRILE NEUTROPENIA; FEMALE; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; LIVER TOXICITY; LYMPHOPROLIFERATIVE DISEASE; MALE; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION;

ADULT; AGED; BLOOD TRANSFUSION; COST-BENEFIT ANALYSIS; ERYTHROPOIETIN; FEMALE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; KINETICS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PLATELET COUNT; STEM CELL TRANSPLANTATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 6444232245     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704643     Document Type: Article

References (37)

1. Freeman MB, Vose J, Bennett C et al. Costs of care for high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 through 1995. Bone Marrow Transplant 1999; 24: 679-684.
2. Gianni AM, Siena S, Bregni M et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2 580-585.
3. Weaver CH, Birch R, Greco FA et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol 1998; 100: 338-347.
4. Waller CF, Bertz H, Wenger MK et al. Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen. Bone Marrow Transplant 1996; 18: 279-283.
5. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339 640-644.
6. Spitzer G, Adkins DR, Spencer V et al. Randomized study of growth factors post-peripheral blood stem cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12: 661-670.
7. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetic as a function of the CD34 content of peripheral blood peripheral cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 10: 3961-3969.
8. Klumpp TR, Mangan KF, Goldberg SL et al. Granulocyte colony-stimulating factors accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13: 1323-1327.
9. McQuaker IG, Hunter AE, Pacey S et al. Low dose Filgastrim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economical benefit. J Clin Oncol 1997; 15: 451-457.
10. Shimazaki C, Oku N, Uchiyama H et al. Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1994; 13: 271-275.
11. Gomez AT, Jimenez MA, Alvarez MA et al. Optimal timing of granulocyte colony-stimulating factors (G-CSF) administration after bone marrow transplantation: a prospective randomized study. Ann Hematol 1995; 71: 65-70.
12. Khwaja A, Mills W, Leverdige AH et al. Efficacy of delayed granulocyte colony-stimulating factor after autologous BMT. Bone Marrow Transplant 1993; 11: 479-482.
13. Olivieri A, Offidani M, Montanari M et al. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica 1998; 83: 329-337.
14. Linch Dc, Watts MJ, Sullivan AM et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quantity and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 2: 535-546.
15. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
16. Shpall E, Jones RB. Release of tumor cells from bone marrow. Blood 1994; 83: 623-625.
17. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636.
18. Pierelli L, Perillo A, Greggi S et al. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomised comparison. J Clin Oncol 1999; 17: 1288.
19. Miller CB, Lazarus HM. Erythropoietin in stem cell transplantation. Bone Marrow Transplant 2001; 27: 1011-1016.
20. Balducci L, Extern M. Management of cancer in the older person: a pratical approach. Oncologist 2000; 5: 224-236.
21. Montanari M, Capelli D, Poloni A et al. Long-term hematologic reconstitution after autologous peripheral blood progenitor cell transplantation: a comparison between controlled-rate freezing and uncontrolled-rate freezing at 80 degrees C. Transfusion 2003; 43 42-49.
22. Capelli D, Santini G, De Souza C et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. Br J Haematol 2000; 110: 300-307.
23. Hornedo J, Sola C, Solano C et al. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period. Bone Marrow Transplant 2002; 29: 737-743.
24. Morabito F, Martino M, Stelitano C et al. Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica 2002; 87: 1192-1199.
25. Vey N, Molnar S, Faucher C et al. Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation: effect on granulocyte recovery. Bone Marrow Transplant 1994; 14: 779-782.
26. Cortellazzo S, Viero P, Bellavita P et al. Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. J Clin Oncol 1995; 4: 935-941.
27. Kessinger A, Sharp G. Mobilization of hematopoietic progenitor cells with epoetin alfa. Semin Haematol 1996; 33 (Suppl 1): 10-15.
28. Olivieri A, Offidani M, Cantori I et al. Addition of erythropoietin to granulocyte colony-stimulating factor after priming chemotherapy enhances hemopoietic progenitor mobilization. Bone Marrow Transplant 1995; 16: 765-770.
29. Hellstrom-Lindberg E, Ahlgren T, Beguin Y et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92: 68-75.
30. Casadevall N, Durieux P, Dubois S et al. Effects of erythropoietin (rHuEpo) plus granulocyte colony stimulating factor (rHuG-CSF) for the treatment of myelodysplastic syndromes (MDS) on anemia, costs and quality of life: a randomized controlled trial. Blood 2004; (Epub ahead of print).
31. Thompson JA, Gilliland DG, Prchal JT, et al, and the GM/EPO MDS Study Group. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patient with myelodisplastic syndrome. Blood 2000; 95: 1175-1179.
32. Link H, Boogaerts M, Fause AA et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 1994; 84: 3327.
33. Chao N, Schriber JR, Long GD et al. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood 1994; 83: 2823.
34. Vannucchi AM, Bosi A, Ieri A et al. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. Bone Marrow Transplant 1996; 17: 527-531.
35. Reiffers J, Cailliot C, Dazey B et al. Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells. Lancet 1999; 354: 1092-1093.
36. Bertolini F, Battaglia M, Pedrazzoli P et al. Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. Blood 1997; 89: 2679-2688.
37. Blair A, Baker CL, Pamphilon DH et al. Ex vivo expansion of megakaryocyte progenitor cells from normal bone marrow and peripheral blood and from patients with haematological malignancies. Br J Haematol 2002; 116: 912-919.